Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Melatonin prolonged-release(Circadin) | Phase 3 | Melatonin receptor (MT1/MT2) | Indication not yet linked |
| Phase 2/3 | MT1/MT2/5-HT1A/1D receptorsSmall molecule | Alzheimer's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.